Posted: Tuesday, August 23, 2022
The first-in-class, central nervous system–active TRK inhibitor larotrectinib seemed to be safe and active in patients with TRK fusion–positive salivary gland tumors of various histologies, according to Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues. These results, which were published in the journal The Oncologist, support NTRK gene fusion testing in those with advanced disease.
“For patients with advanced salivary gland cancer, systemic treatment options are largely limited to doublet chemotherapy regimens, with poor outcomes,” the investigators remarked. “Larotrectinib represents a new precision oncology approach for patients with salivary gland tumors carrying NTRK gene fusions.”
A total of 24 patients with ETV6-NTRK3 gene fusion–positive salivary gland cancer who were treated with larotrectinib were identified from two clinical trials. The most common histologies were secretory carcinoma (54%), adenocarcinoma (25%), and mucoepidermoid carcinoma (13%).
The objective response rate was 92%. The best overall response was a complete response in 13% of patients, a partial response in 79%, and progressive disease in 8%. At a median follow-up of 30.9 months, the 24-month progression-free survival rate was 78%. Most treatment-related adverse events were of grade 1 or 2, and no patients discontinued treatment due to toxicities.
Disclosure: For full disclosures of the study authors, visit academic.oup.com.